# Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

> **NCT02273362** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Cirrhosis
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02273362
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-24
- **Primary completion:** 2020-02-11
- **Final completion:** 2022-03-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273362, "Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02273362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*